Clavis Pharma

Skyline, Clavis collaborate in Leukemia research

Tuesday, September 6, 2011

The Dutch biotech company Skyline Diagnostics and the Norwegian drug development company Clavis Pharma have signed a research agreement. Under this agreement, Skyline will investigate gene expression biomarkers for selection of individual Acute Myeloid Leukemia (AML) patients that may benefit from a new AML drug in development at Clavis. This drug, elacytarabine, is a novel elaidic acid derivative of cytarabine and currently undergoing the CLAVELA phase III study for treatment of patients with relapsed/refractory AML.

[Read More]